Real life results of direct-acting oral anticoagulants recommended-dose in obese vs normal-weight patients with venous thromboembolism
- 5 December 2023
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 233, 165-172
Abstract
No abstract availableKeywords
Funding Information
- Sanofi España
This publication has 41 references indexed in Scilit:
- Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsBritish Journal of Clinical Pharmacology, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Risk Factors for Venous ThromboembolismCirculation, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE registryJournal of Thrombosis and Haemostasis, 2008
- Cardiovascular Risk Factors and Venous ThromboembolismCirculation, 2008
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- Risk factors for pulmonary embolismThe American Journal of Medicine, 1983